Gangolli Julian S 4
4 · Krystal Biotech, Inc. · Filed May 22, 2024
Insider Transaction Report
Form 4
Gangolli Julian S
Director
Transactions
- Exercise/Conversion
Common Stock
2024-05-20$22.75/sh+20,000$455,000→ 20,000 total - Sale
Common Stock
2024-05-20$164.34/sh−7,090$1,165,180→ 1,980 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-20−20,000→ 0 totalExercise: $22.75Exp: 2029-03-01→ Common Stock (20,000 underlying) - Sale
Common Stock
2024-05-20$165.76/sh−1,980$328,200→ 0 total - Sale
Common Stock
2024-05-20$163.71/sh−10,930$1,789,310→ 9,070 total
Footnotes (4)
- [F1]The transaction was executed in multiple trades ranging from $163.080 to $164.065. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F2]The transaction was executed in multiple trades ranging from $164.085 to $164.850. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The transaction was executed in multiple trades ranging from $165.160 to $166.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The options were awarded on March 1, 2019 and vested monthly over a three-year period.